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A Ab bs st tr ra ac ct t
Warfarin and other coumarin anticoagulants are widely used clinically, but currently dosing is
determined individually on the basis of patient response. There is increasing evidence that genetic
factors, together with several non-genetic patient-specific factors, are important determinants of
stable dose requirement for these compounds. Genotype for CYP2C9, which encodes the main
cytochrome P450 enzyme that metabolizes warfarin, and VKORC1, the gene encoding the
warfarin target vitamin K epoxide reductase, together account for approximately 30% of the
variability in dose requirement. The past two years have seen several advances in the area of
genetic factors affecting coumarin anticoagulant response. In particular, prospective studies have
taken place to analyze whether earlier small retrospective studies can be confirmed, and the
question of whether genes other than CYP2C9 and VKORC1 are important in determining dose
requirement has been examined. So far, no strong evidence that other genes contribute to dose
requirement has been found, apart from a minor but novel role for another cytochrome P450
gene, CYP4F2. A recently published whole genome association study confirms that the main
genes important in warfarin response are CYP2C9 and  VKORC1. Clinical trials comparing
genotype-guided and conventional warfarin initiation have suggested that genotyping may be of
value, but larger studies are still needed to show clear clinical benefit. Current knowledge of
genetic factors affecting other coumarin anticoagulants is more limited and this area requires
further study, as does the impact of ethnic variation in genes relevant to coumarin responses.
Here we review recent advances in the area of coumarin anticoagulant genetics and its potential
clinical application.
I In nt tr ro od du uc ct ti io on n
Coumarin anticoagulants, including warfarin, are among the
most widely prescribed drugs in modern medicine. A
difficulty with their use is that dosage needs to be indi-
vidually determined for each patient, usually by following a
standard initial dosing protocol, measuring the coagulation
rate regularly (using the international normalized ratio, INR,
which is a measure of prothrombin time. A high INR value
indicates overcoagulation) and then adjusting the dose until
the required rate of coagulation is obtained. Overcoagulation
places the patient at risk of potentially fatal hemorrhage, so
improving protocols for initiation of anticoagulant treatment
remains an important issue. In particular, warfarin has been
shown to be frequently implicated in emergency admissions
relating to adverse drug reactions in a survey of two UK
hospitals [1]. Approximately 10% of Europeans require an
unusually low dose of warfarin (1.5 mg/day or less) and
these patients could be at increased risk of developing
serious bleeds and undesirably high levels of anticoagu-
lation, especially during the initial weeks of treatment [2].
Although the current oral coumarin anticoagulants, such as
warfarin, acenocoumarol and phenprocoumon, are likely to
be replaced eventually by other drugs under development,
such as the specific thrombin inhibitors, the current drugs
will probably continue to be the main oral anticoagulants
prescribed in the short to medium term.
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coagulants is well understood, with the cytochrome P450
enzyme CYP2C9 having a major role in their phase I
metabolism (reviewed in [3]). CYP2C9 is subject to a genetic
polymorphism affecting its activity, and the fact that this
polymorphism contributes to individual anticoagulant dose
requirement is now well established, although its effect on
phenprocoumon metabolism is less pronounced than that on
either warfarin or acenocoumarol [2,4-7]. Coumarin anti-
coagulants exert their effect by inhibiting the enzyme
vitamin K epoxide reductase, which regenerates vitamin K
following its oxidation in the gamma glutamyl carboxylase
reaction. This reaction takes place during the normal activa-
tion of clotting factors in the coagulation cascade [8]. VKORC1,
the gene encoding the target enzyme vitamin K epoxide
reductase, was identified relatively recently, in 2004 [9].
Polymorphisms in this gene’s non-coding sequences have
been shown to affect levels of gene expression, resulting in
inter-individual variation in the amount of this protein
present in hepatocytes [10], and recent studies have shown
the basis for this: an allele with an A at position -1639
(upstream of the transcription start site) is associated with
lower transcription than the G found more commonly in
European populations [11,12]. VKOR protein levels seem to
affect the required dose of anticoagulant. A clear association
between the G-1639A polymorphism and warfarin dose
requirement has been reported in many independent studies
[10,13,14], and similar associations for acenocoumarol and
phenprocoumon also occur [11,15].
In addition to the contribution of CYP2C9 and VKORC1 to
the coumarin anticoagulant dose requirement, there is clear
evidence for a contribution by other patient-specific factors,
including age, weight, height, concurrent drug therapy and
possibly diet [10,14,16,17]. Worldwide, warfarin is the most
commonly used of the three coumarins and has also been the
most widely studied in relation to factors affecting dose
requirement and various aspects of patient response. The
literature on pharmacogenetic aspects of coumarin anti-
coagulants continues to expand rapidly. An important recent
development is the inclusion of reference to genetic factors
affecting response (both CYP2C9 and  VKORC1) in the
prescribing information for warfarin in the USA by the Food
and Drug Administration (FDA) [18], which is likely to
prompt more interest and further studies in the area.
Detailed background information on coumarin anticoagu-
lants is provided in several recent review articles [19-21].
S St tu ud di ie es s   o of f   t th he e   e ef ff fe ec ct t   o of f   g ge en ne es s   o ot th he er r   t th ha an n   C CY YP P2 2C C9 9 a an nd d
V VK KO OR RC C1 1 o on n   w wa ar rf fa ar ri in n   r re es sp po on ns se e
There is general agreement among published retrospective
population studies that the combination of VKORC1 and
CYP2C9 genotype, together with age, body mass index or
height or weight, and concurrent medication, predicts approxi-
mately 50% of warfarin dose requirement. Identifying
additional factors affecting dose requirement, particularly
genetic factors, is of considerable interest. Some additional
genes (for a detailed list see [20]) have been suggested to
contribute to dose but, in all cases, the observed effects are
smaller than those seen for VKORC1 and  CYP2C9 and,
generally, the findings have not been independently con-
firmed by additional studies.
One possible exception to this is the cytochrome P450
CYP4F2 gene. This gene was shown to contribute to warfarin
dose requirement in a study using the Affymetrix ADME
gene chip, which includes a single nucleotide polymorphism
(SNP) in CYP4F2 that is associated with the amino acid
change V433M [22]. The effect for warfarin was observed in
three independent populations, and it was found that in each
case there was an average 1 mg/day increase in dose require-
ment in those homozygous for the variant compared with
those homozygous for the wild-type allele. Further support
for a minor role for this polymorphism in warfarin dose
requirement has come from a whole genome association
study [23] and from a separate UK-based retrospective study
(Hatch E, AKD and Kamali F, unpublished results).
A problem with this association is that the biological basis
remains unclear. CYP4F2 has a well established role in
eicosanoid metabolism, producing 20-hydroxyeicosatetraenoic
acid, and the V433M polymorphism seems to be functionally
significant, decreasing activity [24]. However, its relevance
to warfarin action is still unclear, although a role for CYP4F2
in vitamin K metabolism has been suggested [22] and it also
remains possible that it contributes directly to warfarin
metabolism. Interestingly, several independent studies suggest
that the CYP4F2 genotype affects systolic blood pressure
[25,26], and an increased risk of ischemic stroke has been
suggested among those positive for the variant form asso-
ciated with the higher warfarin dose requirement [26]. The
effect of CYP4F2 on warfarin dose requirement is biologi-
cally interesting, but the overall 1-2% contribution to dose
requirement confirmed so far [22] may be too small for
genotyping for the relevant SNP to be clinically useful.
A recent whole genome association study on patients treated
with warfarin [23] provides some new insights into the
likelihood of additional genetic effects, and at least two other
such studies are currently under way. In particular, a
published study [23] confirmed the large effect of VKORC1
on dose requirement. No other genome region showed p-
values lower than the significance threshold set by Bon-
ferroni correction in both the original population studied
and a replication population, indicating that only this region
was significantly associated with dose requirement. How-
ever, SNPs in the CYP2C locus gave a moderate p-value in
the original population and showed stronger effects lower
than the significance threshold in both the replication cohort
and the original population combined with the replication
cohort. Evidence for a minor role for CYP4F2 was also
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R Re ec ce en nt t   l la ar rg ge e- -s sc ca al le e   p po op pu ul la at ti io on n   s st tu ud di ie es s   a an nd d   p pr ro op po os sa al ls s   f fo or r
n ne ew w   d do os si in ng g   a al lg go or ri it th hm ms s
Following the discovery of VKORC1, several studies pro-
posed dosing algorithms on the basis of VKORC1 and
CYP2C9 genotypes together with patient-specific non-
genetic factors, such as age, body size and other prescribed
drugs [14,27]. However, these studies were generally based
on small sample numbers and retrospective study designs,
which could limit their widespread usefulness. Some recent
approaches aim to improve on these proposed algorithms by
inclusion of larger numbers of patients and by using pros-
pective study designs [27]. In addition, the International
Warfarin Pharmacogenetics Consortium [28] has pooled
genetic data relating to warfarin from researchers worldwide
to develop a dosing algorithm that will be more applicable to
a range of different ethnic groups. The current dataset
includes data from more than 5,000 patients and quality
control of genotyping has been performed to ensure that all
the data are comparable. One caveat about this approach
concerns the original study designs. Most were retrospective
and somewhat selective in the patients they included, which
could limit the applicability of the algorithm to patients for
whom the stabilization of the drug is more difficult to
achieve. Prospective studies in which patients are recruited at
the start of their treatment are likely to eliminate this issue.
In the largest prospective study yet published [27], involving
1,496 Swedish patients and genotyping for a range of SNPs
in 29 candidate genes, the only significant genetic predictors
of dose were SNPs in CYP2C9 and VKORC1. An algorithm
for dose was developed and used the significant genotypes
together with age, sex (as a surrogate for body mass) and
additional drugs. This large study also demonstrated a
particular risk for high INR (overcoagulation) soon after treat-
ment in individuals homozygous for the variant CYP2C9*3.A
second prospective study [29] involved a smaller sample and
more limited genotyping but also showed a relationship
between CYP2C9 genotype and high INR while suggesting
that individuals homozygous for A-1639 of VKORC1 were
particularly at risk of overcoagulation soon after the start of
treatment.
C Cl li in ni ic ca al l   t tr ri ia al ls s   i in nc co or rp po or ra at ti in ng g   g ge en no ot ty yp pi in ng g
With the development of warfarin dosing algorithms that
incorporate genotyping, clinical trials have been initiated to
investigate their usefulness in warfarin treatment. The
decision by the FDA to include reference to genetic testing in
warfarin’s label is an additional impetus to perform these
studies. Of several factors that need to be taken into account
in order to maximize the usefulness of any clinical trial on
the value of genotype-guided dosing, the main one is the
precise questions to be asked. Will genotyping increase
patient safety, or is the benefit more likely to lie in the area
of economics because fewer consultations or, in some cases,
a shorter hospital stay is needed?
Three published clinical trials [30-32] have focused on the
question of whether genotyping will lead to patients spend-
ing more time in the therapeutic range (the dose that gives
the best effects without side-effects) and achieving a stable
dose sooner, and all three have addressed this using rela-
tively small numbers of patients. The first study [30] looked
at  CYP2C9 genotype only and adjusted dose according to
genotype on the second day of treatment. A total of 95 dose-
adjusted patients and 96 control patients were studied.
Patients with the CYP2C9 genotype-adjusted dose achieved
stable dose sooner, spent more time in the target INR range
and experienced less minor bleeding. In a study using both
CYP2C9 and  VKORC1 genotyping [31], in which genotype
was used to determine intervention on day 3 of dosing, no
difference in the incidence of out-of-range INRs was seen
between 100 patients on a genotype-guided dose and 100 on
a traditional standard protocol. However, some benefits
were shown both for patients homozygous for both wild-type
alleles and for carriers of multiple variant alleles, which
raises the possibility that the failure to see overall signifi-
cance might be due to insufficient statistical power. A non-
randomized prospective study of a similar size but using a
different protocol, with dose adjustment on day 4 of treat-
ment on the basis of either clinical factors only or clinical
factors combined with genotype [32], reported more time
spent in the therapeutic range in the genotype-guided group.
All three trials [30-32] have predominantly involved popula-
tions of European origin, but a prospective study based in
Taiwan involving genotype-guided dosing without a non-
genotyped control group has also been reported [33]. In this
study, 83% of 108 patients reached a stable INR within two
weeks without any bleeding incidents reported. The majority
of patients in that study [33] were homozygous wild type for
CYP2C9 and also homozygous for the VKORC1 variant
genotype, which limited the ability to study patients who
might be particularly at risk of high INR.
There is a need for larger prospective studies to provide
adequate power to look at the incidence of bleeding events
and also to collect information on the economic value of
genotyping. In addition, the application of genotyping prior
to acenocoumarol and phenprocoumon prescription needs
to be assessed, although suitable dosing algorithms will need
to be formulated. No algorithm that uses genotype to predict
a suitable loading dose for use on day 1 has yet been
developed, but such algorithms could be important in
maximizing the benefit of using genotype to guide
anticoagulant dose.
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Progress on our understanding of the genetic factors affect-
ing anticoagulant response has been rapid since the
discovery of the VKORC1 gene in 2004. The availability of
genome-wide association data and large prospective studies
in relation to warfarin have provided an excellent framework
for further research. All indications suggest that incorpora-
ting genetic testing into warfarin use will probably be
beneficial, but the extent of that benefit still needs to be
determined in well-designed clinical trials if testing is to
become routine in clinical practice.
The use of genetic tests in relation to drug prescription
remains confined to some very specific examples, mainly in
oncology [34]. Warfarin is prescribed more commonly than
any of the drugs for which genetic testing is already widely
used, and adoption of routine genetic testing during
initiation of dosing would be an important advance clini-
cally. Acenocoumarol and phenprocoumon continue to be
the main oral anticoagulants used in several European coun-
tries, and further studies to bring understanding of genetic
factors affecting response to these compounds up to the level
currently available for warfarin is desirable. Finally, if a
useful algorithm involving genetic testing that will benefit all
users of coumarin anticoagulants is to be finalized, it will
also be important to assess its validity in a range of different
ethnic groups.
A Ab bb br re ev vi ia at ti io on ns s
CYP2C9, cytochrome P450 2C9; FDA, Food and Drug
Administration; INR, International normalized ratio; SNP,
single nucleotide polymorphism; VKORC1, vitamin K
epoxide reductase complex 1.
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